This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Lena Chaihorsky, BS
Advertisement
Articles by Lena Chaihorsky, BS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity
2
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
3
Type 5 Diabetes: A Long-Ignored Condition Gets Its Moment
4
AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike
5